SPY313.77-3.28 -1.03%
DIA259.16-3.84 -1.46%
IXIC10,343.89-89.76 -0.86%

Schrödinger Announces Strategic Collaboration With Thermo Fisher Scientific To Expand Structure-Based Drug Discovery To Novel Targets Using Cryo-EM

Schrödinger (NASDAQ:SDGR) today announced a strategic collaboration with Thermo Fisher Scientific to extend the use of cryo-EM in connection with in silico compound screening to accelerate drug

Benzinga · -

Schrödinger (NASDAQ:SDGR) today announced a strategic collaboration with Thermo Fisher Scientific to extend the use of cryo-EM in connection with in silico compound screening to accelerate drug discovery.

The collaboration brings together Schrödinger's physics-based software platform with Thermo Fisher's world-leading cryo-EM technology to expand the applicability of structure-based drug discovery to a wider array of targets which may not be amenable to structure prediction via x-ray crystallography. Schrödinger will identify drug discovery targets and Thermo Fisher will obtain cryo-EM structures of these targets with bound ligands. Schrödinger will then leverage its advanced computational platform, together with the cryo-EM structures, to identify development candidates.

"This collaboration is of high strategic importance not only to Schrödinger and Thermo Fisher, but to the broad field of drug discovery," said Robert Abel, Ph.D., Executive Vice President of Science at Schrödinger. "Cryo-EM is a powerful tool and this collaboration will pave the way toward using it on an expanded set of important drug targets."

"This is an exciting moment for the field," said Trisha Rice, Vice President and General Manager of Life Sciences at Thermo Fisher. "We're delighted to be working with Schrödinger to optimize the synergies between cryo-EM's efficient elucidation of protein structures and the rapid cycles of compound optimization made possible by computational modeling. We expect this collaboration to open new doors for structure-based drug discovery."